Method for producing a population of homozygous stem cells having a pre-selected immunotype and/or genotype, cells suitable for transplant derived therefrom, and materials and methods using same

• US 7,030,292 B2
• Filed: 01/02/2002
• Issued: 04/18/2006
• Est. Priority Date: 01/02/2001
• Status: Expired due to Fees

• Current Assignee: Stemron Incorporated
• Original Assignee: Stemron Incorporated
• Inventors: Lei, Jingqi, Yan, Wen Liang, Huang, Steve Chien-Wen, Nguyen, Minh-Thanh, Khanna, Ruchi, Lin, Huan (Helen)
• Primary Examiner(s): LI, QIAN JANICE
• Application Number:
  US10/032,495
• Publication Number:
  US 20020155601A1
• Time in Patent Office: 1,567 Days
• Field of Search: 424/93.1, 435/325, 435/373, 435/376, 435/377, 800/22
• US Class Current: 800/24
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C12N 2501/125 Stem cell factor [SCF], c-kit ligand [KL]
• CPC Class Codes: C12N 2502/13 connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
• CPC Class Codes: C12N 2506/04 from germ cells
• CPC Class Codes: C12N 2506/30 from cancer cells, e.g. reversion of tumour cells
• CPC Class Codes: C12N 5/0603 Embryonic cells production of embryos, nuclear transfer A01K67/027; Embryoid bodies

Abstract

A method of producing a homogenous population of homozygous stem (HS) cells pre-selected for immunotype and/or genotype from donor cells is described herein. The invention relates to methods of using immunohistocompatible HS cells for diagnosis, therapeutic and cosmetic transplantation, and the treatment of various genetic diseases, neurodegenerative diseases, traumatic injuries and cancer. The invention further relates to methods for using histocompatible HS stem cells pre-selected for a non-disease genotype for prophylactic and therapeutic intervention including, but not limited to, therapeutic and cosmetic transplantation, and the treatment of various genetic diseases, neurodegenerative diseases, and cancer. Furthermore, the invention relates to a catalogued transplant depository of HS cells derived from multiple donors, each of the HS cells being homozygous for a unique HLA haplotype, for the purpose of having a constant, reliable, comprehensive supply of immunohistocompatible cells for diagnosis, treatment and/or transplantation.

Claims

1. A method for producing a mammalian homozygous embryonic stem (HES) cell depository, wherein each HES cell produces a cell line, which has alleles that are homozygous for a Major Histocompatibility Complex (MHC) haplotype, wherein the method comprises:

(a) selecting donors;

(b) determining the MHC haplotype of each donor;

(c) mitotically activating non-fertilized post-meiosis I diploid oocytes obtained from each donor to develop multiple blastocyst-like masses, each of which contains an inner cell mass (ICM) that is homozygous for a particular MHC haplotype, wherein the non-fertilized post-meiosis I diploid oocytes are subject to sham intracytoplasmic sperm injection (ICSI) followed by incubation with calcium ionophore;

(d) isolating HES cells from the ICM obtained from each donor;

(e) culturing the isolated HES cells to obtain HES cell lines;

(f) determining the MHC haplotype of each HES cell line; and

(g) cataloging the MHC haplotype of each HES cell line obtained in (e).

2. The method of claim 1, wherein the donors are human.

3. The method of claim 1, wherein the donors are non-human.